Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice.

Vaccines (Basel) · 2021 · PMC8225126 · PMID 34070277

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach conventional levels of significanceno p-value reported

They concluded that the gB/MF59 vaccine was safe and immunogenic, although the efficacy did not reach conventional levels of significance and was not sufficient to continue the development of this vaccine [ 115 ]. 2.3.

also in 76 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.